Non-pharmacological therapy of idiopathic inflammatory myopathies – exercise and its effect on patients with IIM, from 1993 to 2018
Authors:
M. Špiritović 1; H. Alexanderson 2; H. Štorkánová 3,4; S. Oreská 3,4; B. Heřmánková 1; Mw Romanowski 5; D. Pavlů 1; M. Olejárová 3,4; M. Tomčík 3,4
Authors‘ workplace:
Katedra fyzioterapie, Fakulta tělesné výchovy a sportu, Univerzita Karlova, Praha, Česká republika
1; Function area Occupational therapy and Physical therapy, Karolinska University Hospital and Division of Physical therapy, Department of NVS, Karolinska Institutet, Huddinge and Division of Rheumatology, Department of Medicine, Solna, Stockholm, Sweden
2; Revmatologický ústav, Praha, Česká republika
3; Revmatologická klinika 1. lékařské fakulty, Univerzita Karlova, Praha, Česká republika
4; Department of Rheumatology and Rehabilitation, Poznan University of Medical Sciences, Poznań, Poland
5
Published in:
Čes. Revmatol., 26, 2018, No. 4, p. 181-189.
Category:
Review Article
Overview
Idiopathic inflammatory myopathy (IIM) is a rare and very serious heterogeneous group of acquired inflammatory diseases of the skeletal muscle with a different course and prognosis. Based on specific clinical, histopathological, immunological and demographic features, IIM can be divided into three basic subgroups: dermatomyositis (DM), polymyositis (PM), and inclusion body myositis (IBM). IIM is characterized by the presence of painless, symmetrical and predominantly proximal muscular weakness. It also affects the internal organs - most often the lungs, esophagus and heart, as well as the skin in dermatomyositis. An important burden for the IIM patients is, in particular, the reduction of muscle function and strength, the reduction of aerobic capacity, the loss of quality of life and persistent disability. The cause of these diseases is unknown and there is no effective universal treatment yet. Current pharmacological approaches in IIM have only a limited effect on muscle involvement and non-pharmacological therapy, as recent studies show, can be very useful in reducing disability, improving quality of life, and can also contribute to reducing the burden of the disease. However, the limitations of most existing studies dealing with non-pharmacological treatment of IIM patients are poor methodological quality, insufficient number of patients, absence of a control group or lack of follow-up and short-term intervention. The purpose of this review article is to introduce important work that dealt with the safety and benefits of various non-pharmacological approaches (exercises) that are at the forefront of interest in clinical research on IIM.
Key words:
idiopathic inflammatory myopathy, inclusion body myositis, polymyositis, dermatomyositis, juvenile dermatomyositis, rheumatic diseases, exercise training, aerobic exercise, rehabilitation, physiotherapy, non-pharmacological therapy
Sources
1. Gazeley DJ, Cronin ME. Diagnosis and treatment of the idiopathic inflammatory myopathies. Ther Adv Musculoskeletal Dis2011; 3(6): 315–24.
2. LundbergIE, Vencovsky J, Alexanderson H. Therapy of myositis: biological and physical. Curr Opin Rheumatol2014; 26(6): 704–11.
3. MauW, Listing J, Huscher D, Zeidler H, Zink A. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol2005; 32(4): 721–8.
4. Rider LG, Katz JD, Jones OY. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2013; 39(4): 877–904.
5. Zong M, Lundberg, IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011; 7(5): 297–306.
6. Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol 2012; 24(6): 635–41.
7. Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheumatol Rep 2012; 14(3): 244–51.
8. Gualano B, Neves M Jr, Lima FR, Pinto AL, Laurentino G, Borqes C, et al. Resistance training with vascular occlusion in inclusion body myositis: a case study. Med Sci Sports Exerc 2010; 42(2): 250–4.
9. Voet N, van der Kooi EL, Riphagen II, Lindeman E, van Engelen BG, GeurtsACh. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev 2010; (1): CD003907.
10. Alemo Munters L, Dastmalchi M, Andgren V, Emilson C, Bergegård J, Regardt M, et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicentre randomized controlled trial with a 1–year open extension follow-up. Arthritis Care Res (Hoboken) 2013; 65(12): 1959–68.
11. Alexanderson H, Munters LA, Dastmalchi M, Loell I, Heimbürger M, Opava CH, et al. Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis—a randomized controlled single-blinded study with a 2-year follow up. JRheumatol2014; 41(6): 1124–32.
12. Munters LA, Dastmalchi M, Katz A, Esbjörnsson M, Loell I, Hanna B et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther 2013; 15(4): R83.
13. Hicks J, Miller F, Plotz P, Chen TH, Gerber L, et al. Isometric exercise increases strength and does not produce sustained creatinine phosphokinase increases in a patient with polymyositis. J Rheumatol 1993; 20(8): 1399–401.
14. Escalante A, Miller L, Beardmore T. Resistive exercise in the rehabilitation of polymyositis/dermatomyositis. J Rheumatol1993; 20(8): 1340–1344.
15. Wiesinger G, Quittan M, Aringer M, Seeber A, Volc-Platzer B, Smolen J, et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998; 37(2): 196–200.
16. Wiesinger G, Quittan M, Graninger M, Seeber A, Ebenbichler G, Sturm B, et al. Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol 1998; 37(12): 1338–42.
17. Alexanderson H, Stenström C, Lundberg I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology (Oxford) 1999; 38(7): 608–11.
18. Alexanderson H, Stenström CH, Jenner G, Lundberg I. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000; 29(5): 295–301.
19. Wiesinger GF, Quittan M, Nuhr M, Volc-Platzer B, Ebenbichler G, Zehetgruber M, et al. Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls. Arch Phys Med Rehabilitation 2000; 81(1): 1–5.
20. Karper WB, Hopewell R, Hodge M. Exercise program effects on one woman with dermatomyositis. Rehabilitation Nursing J2001; 26(4):129–131.
21. Heikkillä S, et al. Rehabilitation in myositis: preliminary study. Physiotherapy 2001; 87(6):301–309.
22. Varjú C, Pethö E, Kutas R, Czirják L. et al. The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil 2003; 17(1):83–87.
23. Harris–Love, MO. Safety and efficacy of submaximal eccentric strength training for a subject with polymyositis. Arthritis Care Res 2005; 53(3):471–4.
24. Dastmalchi M, et al. Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Care Res 2007; 57(7): 1303–10.
25. Alexanderson H, et al. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Care Res 2007; 57(5):768–77.
26. Miller F, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatol 2001; 40(11): 1262–73.
27. Rider LG et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheumatol 2004 50(7): 2281–90.
28. Nader GA, et al. A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis. Molecul Med 2010; 16(11-12): 455.
29. Dalise S, et al. Intensive aerobic training improves motor performances and oxidative metabolism efficiency in chronic polymyositis: a case report. Neuromuscular Disorders 2012; 22: S221–5.
30. Hejazi SMA, Engkasan JP, Qomi MSM. Intensive exercise and a patient in acute phase of polymyositis. J Back Musculoskeletal Rehabilitation 2012; 25(4):231–4.
31. Mattar MA, et al. Exercise as an adjuvant treatment in persistent active polymyositis. JCR: J ClinRheumatol2014; 20(1): 11–5.
32. Mattar MA, et al. Safety and possible effects of low-intensity resistance training associated with partial blood flow restriction in polymyositis and dermatomyositis. Arthritis Res Therapy 2014; 16(5):473.
33. Bertolucci F, et al. Abnormal lactate levels in patients with polymyositis and dermatomyositis: the benefits of a specific rehabilitative program. Eur J Physical Rehabilitation Med 2014; 50(2): 161–9.
34. Boehler JF, et al. Effect of endurance exercise on microRNAs in myositis skeletal muscle–a randomized controlled study. PloS one 2017; 12(8): e0183292.
35. Chung Yl, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six–month, double–blind, randomized, placebo–controlled trial. Arthritis Care Res 2007; 57(4):694–702.
36. Regardt M, et al. Hand exercise intervention in patients with polymyositis and dermatomyositis: a pilot study. Musculoskeletal Care 2014; 12(3):160–72.
37. Spector SA, et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997; 20(10): 1242–8.
38. Arnardotti S, et al. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabilitation Med 2003; 35(1): 31–5.
39. Johnson, LG, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscular Dis 2009; 10(4): 178–84.
40. Johnson LG, et al. The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. J Clin Neuromuscular Dis 2007; 8(4):187–94.
41. Takken T, et al. Aerobic exercise capacity in patients with juvenile dermatomyositis. JRheumatol2003; 30(5): 1075–1080.
42. Takken T, Van Der Net J, Helders PJ. Anaerobic exercise capacity in patients with juvenile–onset idiopathic inflammatory myopathies. Arthritis Care Res 2005; 53(2): 173–7.
43. Maillard SM, et al. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Care Res 2005; 53(4): 558–64.
44. Omori C, et al. Responsiveness to exercise training in juvenile dermatomyositis: a twin case study. BMC Musculoskeletal Disorders 2010; 11(1): 270.
45. Omori CH, et al. Exercise training in juvenile dermatomyositis. Arthritis Care Res 2012; 64(8):1186–94.
46. Riisager M, et al. Aerobic training in persons who have recovered from juvenile dermatomyositis. Neuromuscular Disorders 2013; 23(12): 962–8.
47. Habers GEA, et al. Near–infrared spectroscopy during exercise and recovery in children with juvenile dermatomyositis. Muscle Nerve 2013; 47(1):108–15.
48. Berntsen KS, et al. Submaximal exercise capacity in juvenile dermatomyositis after long-term disease: the contribution of muscle, lung, and heart involvement. J Rheumatol2017; 44(6):827–34.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2018 Issue 4
Most read in this issue
- Clinically suspect arthralgia: a current view of the preclinical phase of rheumatoid arthritis
- The Czech Society for Rheumatology standpoint for the treatment with antirheumatic drugs in pregnancy and lactation
- Long-term results of treatment of rheumatoid arthritis with adalimumab in the national ATTRA registry
- Extracellular miRNA – biogenesis, function and their use as biomarkers in rheumatic diseases.